주식회사인투셀 / IntoCell
IntoCell's KOBDi Score is 69.58 as of Sep 2026, up 1.19 points since May 2025; it rose in 6 and fell in 4 of the 11 monthly updates. As of Sep 2026 it is ahead of about 95% of companies in its industry, against 95% in Aug 2026 and 84% in May 2025. Its strongest position was 96% (Jul 2026) and its weakest 84% (May 2025).
A year earlier, in Aug 2025, its score was 68.51 and it was ahead of about 96% of companies in its industry.
| Sep 2026 | 69.58 | ahead of 95% |
| Aug 2026 | 69.37 | ahead of 95% |
| Jul 2026 | 69.62 | ahead of 96% |
| Jun 2026 | 69.62 | ahead of 96% |
| May 2026 | 69.46 | ahead of 96% |
| Apr 2026 | 69.21 | ahead of 96% |
| Mar 2026 | 69.05 | ahead of 96% |
| Feb 2026 | 69.24 | ahead of 96% |
| Dec 2025 | 69.26 | ahead of 96% |
| Aug 2025 | 68.51 | ahead of 96% |
| Jul 2025 | 69.09 | ahead of 85% |
| May 2025 | 68.39 | ahead of 84% |
| # | ||||
|---|---|---|---|---|
| 에이치엔에이치바이오 주식회사 Hnh Bio Co., Ltd. | 50–99 | #61 | ||
| 알지노믹스(주) Rznomics Inc. | 30–49 | #62 | ||
| 갤럭스주식회사 Galux Inc. | 50–99 | #63 | ||
| (주)삼양사 식품연구소 | 30–49 | #59 | ||
| 프레스티지바이오파마아이디씨 주식회사 Prestige BioPharma IDC Co., Ltd | 50–99 | #58 | ||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
| ||||
|
|
Where is IntoCell located?
IntoCell is registered at Sinildong-ro, Daedeok-gu, Daejeon, South Korea (postal code 34324).
How many employees does IntoCell have?
IntoCell has 30–49 employees.
Is IntoCell a public company?
Yes. IntoCell is listed on KOSDAQ under the ticker Not available since 2025.
What is IntoCell's KOBDi Score?
69.58 as of September 2026, ahead of about 95% of companies in its industry.
Who are IntoCell's competitors?
Similar companies include Hnh Bio, Rznomics and Galux.


